Evidence map›Paper›PMID 28074331›Full record

ArticlePathology oncology research : POR2017

A Retrospective Analysis of the First 41 mCRPC Patients with Bone Pain Treated with Radium-223 at the National Institute of Oncology in Hungary.

Zs Küronya, I Sinkovics, P Ágoston, K Bíró, I Bodrogi, I Böde, M Dank, F Gyergyay, T Vajdics, Zs Kolonics and 3 more

Abstract read
PubMed Publisher
In one paragraph

Article in Pathology oncology research : POR, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Zs KüronyaNational Institute of Oncology, Ráth György u. 7-9, Budapest, H-1122, Hungary. kuronyaz@gmail.com.ORCID http://orcid.org/0000-0001-8500-5924
I SinkovicsNational Institute of Oncology, Ráth György u. 7-9, Budapest, H-1122, Hungary.
P ÁgostonNational Institute of Oncology, Ráth György u. 7-9, Budapest, H-1122, Hungary.
K BíróNational Institute of Oncology, Ráth György u. 7-9, Budapest, H-1122, Hungary.
I BodrogiNational Institute of Oncology, Ráth György u. 7-9, Budapest, H-1122, Hungary.
I BödeJahn Ferenc South-Pest Hospital, Budapest, Hungary.
M Dank1st Department of Internal Medicine, Semmelweis University, Budapest, Hungary.
F GyergyayNational Institute of Oncology, Ráth György u. 7-9, Budapest, H-1122, Hungary.
T VajdicsNational Institute of Oncology, Ráth György u. 7-9, Budapest, H-1122, Hungary.
Zs KolonicsTeaching Hospital Mór Kaposi, Kaposvár, Hungary.
K NagyiványiNational Institute of Oncology, Ráth György u. 7-9, Budapest, H-1122, Hungary.
Á RúzsaTeaching Hospital Mór Kaposi, Kaposvár, Hungary.
L GécziNational Institute of Oncology, Ráth György u. 7-9, Budapest, H-1122, Hungary.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Radium-223 dichloride is an alpha-emitting radiopharmaceutical which significantly prolongs overall survival in patients with castration-resistant prostate cancer (CRPC) and symptomatic bone metastases. This was a retrospective analysis of the efficacy and safety of Radium-223 in the first 41 patients treated at a single center in Hungary. Radium-223 was given at a dose of 50 kBq/kg intravenously every 4 weeks for up to 6 cycles. Between 23rd July 2014 and 23rd February 2016, 41 patients were treated. Patient demographics, laboratory values, treatment outcomes and adverse events were collected from medical records. The mean age was 72.2 years (SD: 7.1). 24 patients received Radium-223 as first-line treatment (58%), 7 patients as second (17%), 3 as third (7.3%), 6 as (14.6%), and 1 as fifth-line therapy (2.4%). The mean number of cycles administered was 5.5 (SD: 1.1). The most common side effects were anemia (32% grade 1-3), nausea (28%, grade 1), diarrhea (4%, grade 2), thrombocytopenia (4%, grade 3). The mean baseline PSA level was 307.2 ng/ml (SD: 525.7), which increased to a mean value of 728.5 ng/ml (SD: 1277) by the end of treatment. The baseline mean ALP of 521.1 U/L (SD: 728) decreased to 245.1 U/L (SD: 283.5). The majority of patients experienced a decrease (37%) or complete cessation (43%) of bone pain intensity. In our symptomatic prostate cancer patient population, Radium-223 proved to be efficient in terms of pain relief, with moderate side effects. No PSA response was detected, while alkaline phosphatase levels significantly decreased.

Indexed as

AgedAged, 80 and overAntineoplastic AgentsBone NeoplasmsCancer PainHumansHungaryMaleMiddle AgedProstatic Neoplasms, Castration-ResistantRadioisotopesRadiopharmaceuticalsRadiumRetrospective StudiesAntineoplastic AgentsRadioisotopesRadiopharmaceuticalsRadiumradium Ra 223 dichlorideBone painMetastatic castration-resistant prostate cancer (mCRPC)Radium-223

Identifiers

PMID28074331

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.